These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

856 related articles for article (PubMed ID: 26955859)

  • 1. Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF.
    Pokorney SD; Piccini JP; Stevens SR; Patel MR; Pieper KS; Halperin JL; Breithardt G; Singer DE; Hankey GJ; Hacke W; Becker RC; Berkowitz SD; Nessel CC; Mahaffey KW; Fox KA; Califf RM; ;
    J Am Heart Assoc; 2016 Mar; 5(3):e002197. PubMed ID: 26955859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF).
    Sherwood MW; Douketis JD; Patel MR; Piccini JP; Hellkamp AS; Lokhnygina Y; Spyropoulos AC; Hankey GJ; Singer DE; Nessel CC; Mahaffey KW; Fox KA; Califf RM; Becker RC;
    Circulation; 2014 May; 129(18):1850-9. PubMed ID: 24552831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renal dysfunction as a predictor of stroke and systemic embolism in patients with nonvalvular atrial fibrillation: validation of the R(2)CHADS(2) index in the ROCKET AF (Rivaroxaban Once-daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation) and ATRIA (AnTicoagulation and Risk factors In Atrial fibrillation) study cohorts.
    Piccini JP; Stevens SR; Chang Y; Singer DE; Lokhnygina Y; Go AS; Patel MR; Mahaffey KW; Halperin JL; Breithardt G; Hankey GJ; Hacke W; Becker RC; Nessel CC; Fox KA; Califf RM;
    Circulation; 2013 Jan; 127(2):224-32. PubMed ID: 23212720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation.
    Piccini JP; Hellkamp AS; Washam JB; Becker RC; Breithardt G; Berkowitz SD; Halperin JL; Hankey GJ; Hacke W; Mahaffey KW; Nessel CC; Singer DE; Fox KA; Patel MR
    Circulation; 2016 Jan; 133(4):352-60. PubMed ID: 26673560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
    Halperin JL; Hankey GJ; Wojdyla DM; Piccini JP; Lokhnygina Y; Patel MR; Breithardt G; Singer DE; Becker RC; Hacke W; Paolini JF; Nessel CC; Mahaffey KW; Califf RM; Fox KA;
    Circulation; 2014 Jul; 130(2):138-46. PubMed ID: 24895454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial).
    Bansilal S; Bloomgarden Z; Halperin JL; Hellkamp AS; Lokhnygina Y; Patel MR; Becker RC; Breithardt G; Hacke W; Hankey GJ; Nessel CC; Singer DE; Berkowitz SD; Piccini JP; Mahaffey KW; Fox KA;
    Am Heart J; 2015 Oct; 170(4):675-682.e8. PubMed ID: 26386791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
    Patel MR; Hellkamp AS; Lokhnygina Y; Piccini JP; Zhang Z; Mohanty S; Singer DE; Hacke W; Breithardt G; Halperin JL; Hankey GJ; Becker RC; Nessel CC; Berkowitz SD; Califf RM; Fox KA; Mahaffey KW
    J Am Coll Cardiol; 2013 Feb; 61(6):651-8. PubMed ID: 23391196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Outcome of Patients Receiving Thrombolytic Therapy While on Rivaroxaban for Nonvalvular Atrial Fibrillation (from Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).
    Chen ST; Hellkamp AS; Becker RC; Berkowitz SD; Breithardt G; Fox KAA; Hacke W; Halperin JL; Hankey GJ; Mahaffey KW; Nessel CC; Piccini JP; Singer DE; Patel MR
    Am J Cardiol; 2017 Nov; 120(10):1837-1840. PubMed ID: 28886856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial.
    Kerneis M; Gibson CM; Chi G; Mehran R; AlKhalfan F; Talib U; Pahlavani S; Mir M; Bode C; Halperin JL; Nafee T; Peterson ED; Verheugt FWA; Wildgoose P; van Eickels M; Lip GYH; Fox KAA; Cohen M
    JACC Cardiovasc Interv; 2018 Apr; 11(7):626-634. PubMed ID: 29550085
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Rivaroxaban Versus Warfarin in Patients Taking Nondihydropyridine Calcium Channel Blockers for Atrial Fibrillation (from the ROCKET AF Trial).
    Washam JB; Hellkamp AS; Lokhnygina Y; Piccini JP; Berkowitz SD; Nessel CC; Becker RC; Breithardt G; Fox KAA; Halperin JL; Hankey GJ; Mahaffey KW; Singer DE; Patel MR;
    Am J Cardiol; 2017 Aug; 120(4):588-594. PubMed ID: 28645473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation.
    Nazha B; Pandya B; Cohen J; Zhang M; Lopes RD; Garcia DA; Sherwood MW; Spyropoulos AC
    Circulation; 2018 Oct; 138(14):1402-1411. PubMed ID: 29794081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Higher risk of death and stroke in patients with persistent vs. paroxysmal atrial fibrillation: results from the ROCKET-AF Trial.
    Steinberg BA; Hellkamp AS; Lokhnygina Y; Patel MR; Breithardt G; Hankey GJ; Becker RC; Singer DE; Halperin JL; Hacke W; Nessel CC; Berkowitz SD; Mahaffey KW; Fox KA; Califf RM; Piccini JP;
    Eur Heart J; 2015 Feb; 36(5):288-96. PubMed ID: 25209598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation.
    Hankey GJ; Stevens SR; Piccini JP; Lokhnygina Y; Mahaffey KW; Halperin JL; Patel MR; Breithardt G; Singer DE; Becker RC; Berkowitz SD; Paolini JF; Nessel CC; Hacke W; Fox KA; Califf RM;
    Stroke; 2014 May; 45(5):1304-12. PubMed ID: 24743444
    [TBL] [Abstract][Full Text] [Related]  

  • 14. On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF.
    Fordyce CB; Hellkamp AS; Lokhnygina Y; Lindner SM; Piccini JP; Becker RC; Berkowitz SD; Breithardt G; Fox KA; Mahaffey KW; Nessel CC; Singer DE; Patel MR;
    Circulation; 2016 Jul; 134(1):37-47. PubMed ID: 27358435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
    Washam JB; Stevens SR; Lokhnygina Y; Halperin JL; Breithardt G; Singer DE; Mahaffey KW; Hankey GJ; Berkowitz SD; Nessel CC; Fox KA; Califf RM; Piccini JP; Patel MR;
    Lancet; 2015 Jun; 385(9985):2363-70. PubMed ID: 25749644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AF.
    Chen ST; Hellkamp AS; Becker RC; Berkowitz SD; Breithardt G; Fox KAA; Hacke W; Halperin JL; Hankey GJ; Mahaffey KW; Nessel CC; Piccini JP; Singer DE; Patel MR; Melloni C
    Eur Heart J Qual Care Clin Outcomes; 2019 Apr; 5(2):145-152. PubMed ID: 30219887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of Dual Antiplatelet Therapy and Patient Outcomes in Those Undergoing Percutaneous Coronary Intervention: The ROCKET AF Trial.
    Sherwood MW; Cyr DD; Jones WS; Becker RC; Berkowitz SD; Washam JB; Breithardt G; Fox KA; Halperin JL; Hankey GJ; Singer DE; Piccini JP; Nessel CC; Mahaffey KW; Patel MR
    JACC Cardiovasc Interv; 2016 Aug; 9(16):1694-702. PubMed ID: 27539689
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation).
    Goodman SG; Wojdyla DM; Piccini JP; White HD; Paolini JF; Nessel CC; Berkowitz SD; Mahaffey KW; Patel MR; Sherwood MW; Becker RC; Halperin JL; Hacke W; Singer DE; Hankey GJ; Breithardt G; Fox KA; Califf RM;
    J Am Coll Cardiol; 2014 Mar; 63(9):891-900. PubMed ID: 24315894
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Atrial Fibrillation and Chronic Kidney Disease Stage G4: A Single-Center Experience.
    Heleniak Z; Papuga-Szela E; Krzysztof P; Anetta U
    J Cardiovasc Pharmacol; 2020 Dec; 76(6):671-677. PubMed ID: 33284572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Efficacy of Rivaroxaban in Patients With Cardiac Implantable Electronic Devices: Observations From the ROCKET AF Trial.
    Leef GC; Hellkamp AS; Patel MR; Becker RC; Berkowitz SD; Breithardt G; Halperin JL; Hankey GJ; Hacke W; Nessel CC; Singer DE; Fox KAA; Mahaffey KW; Piccini JP
    J Am Heart Assoc; 2017 Jun; 6(6):. PubMed ID: 28615214
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.